Ken Griffin Adc Therapeutics Sa Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.59 - $4.01 $48,951 - $75,789	-18,900 Reduced 67.74%	9,000 $28,000
Q2 2024 Aug 14, 2024	BUY	$2.55 - $5.09 $765 - $1,527	300 Added 1.09%	27,900 $88,000
Q1 2024 May 15, 2024	BUY	$1.66 - $5.29 $45,816 - $146,004	27,600 New	27,600 $123,000
Q3 2023 Nov 14, 2023	BUY	$0.72 - $2.37 $1,368 - $4,503	1,900 Added 633.33%	2,200 $1,000
Q2 2023 Aug 14, 2023	SELL	$1.9 - $2.66 $760 - $1,064	-400 Reduced 57.14%	300 $0
Q1 2023 May 15, 2023	SELL	$1.92 - $5.45 $9,216 - $26,160	-4,800 Reduced 87.27%	700 $1,000
Q4 2022 Feb 14, 2023	SELL	$2.87 - $5.24 $14,350 - $26,200	-5,000 Reduced 47.62%	5,500 $21,000
Q3 2022 Nov 14, 2022	SELL	$4.66 - $10.31 $43,804 - $96,914	-9,400 Reduced 47.24%	10,500 $51,000

55.1M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $158M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.